Related Experiment Videos
Summary
Adult T cell leukaemia/lymphoma (ATLL) is a cancer caused by human T-lymphotropic virus type I (HTLV-I). This aggressive cancer has a poor prognosis, with a median survival of only 11 months.
Area of Science:
- Oncology
- Virology
- Hematology
Background:
- Adult T-cell leukaemia/lymphoma (ATLL) was first described in the 1970s.
- It is characterized by hypercalcemia, bone disease, opportunistic infections, and multi-organ involvement.
- The malignant T-cells exhibit a unique multilobed morphology.
Purpose of the Study:
- To provide a comprehensive overview of Adult T-cell leukaemia/lymphoma (ATLL).
- To discuss the etiology, clinical presentation, and geographical distribution of ATLL.
- To outline current treatment strategies and prognosis for ATLL patients.
Main Methods:
- Review of epidemiological data and clinical characteristics of ATLL.
- Discussion of the role of human T-lymphotropic virus type I (HTLV-I) in ATLL pathogenesis.
- Analysis of treatment outcomes and survival rates for ATLL.
Main Results:
- ATLL is endemic in the Japanese archipelago, Caribbean, and southeastern USA due to HTLV-I.
- The disease presents in acute, subacute, chronic, or smouldering forms.
- Despite intensive chemotherapy, remission duration is short, with a median survival of 11 months.
Conclusions:
- ATLL is an aggressive malignancy linked to HTLV-I infection.
- Treatment options are limited, and prognosis remains poor.
- Opportunistic infections are a common cause of mortality in ATLL patients.